X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
endocrinology & metabolism (54) 54
humans (22) 22
index medicus (22) 22
male (20) 20
diabetes mellitus, type 2 - drug therapy (18) 18
canagliflozin (17) 17
female (17) 17
middle aged (17) 17
adult (13) 13
diabetes (13) 13
type 2 diabetes (13) 13
aged (12) 12
glycemic control (12) 12
double-blind method (10) 10
glucose (10) 10
type 2 diabetes mellitus (10) 10
dextrose (9) 9
efficacy (9) 9
glycated hemoglobin a - metabolism (9) 9
hypoglycemic agents - administration & dosage (9) 9
insulin (9) 9
internal medicine (9) 9
mellitus (9) 9
treatment outcome (9) 9
body weight (8) 8
diabetes mellitus, type 2 - blood (8) 8
diabetes therapy (8) 8
medicine, general & internal (8) 8
safety (8) 8
sulfonylurea (8) 8
body weight - drug effects (7) 7
dapagliflozin (7) 7
double-blind (7) 7
hypoglycemic agents - therapeutic use (7) 7
metformin (7) 7
monotherapy (7) 7
sodium glucose co-transporter 2 inhibitor (7) 7
add-on (6) 6
adolescent (6) 6
aged, 80 and over (6) 6
blood glucose - drug effects (6) 6
care and treatment (6) 6
drug therapy (6) 6
hypoglycemic agents - adverse effects (6) 6
sitagliptin (6) 6
sodium-glucose transporter 2 - antagonists & inhibitors (6) 6
weight loss - drug effects (6) 6
abridged index medicus (5) 5
background metformin (5) 5
blood glucose - metabolism (5) 5
blood pressure - drug effects (5) 5
dose-response relationship, drug (5) 5
glucosides - adverse effects (5) 5
hypoglycemic agents (5) 5
inhibitor (5) 5
management (5) 5
metformin - therapeutic use (5) 5
original research (5) 5
patients (5) 5
weight control (5) 5
young adult (5) 5
analysis (4) 4
canagliflozin - administration & dosage (4) 4
canagliflozin - therapeutic use (4) 4
cotransporter 2 inhibitor (4) 4
drug therapy, combination (4) 4
endocrinology (4) 4
glipizide (4) 4
glucosides - administration & dosage (4) 4
glucosides - therapeutic use (4) 4
long-term efficacy (4) 4
medicine & public health (4) 4
metformin - administration & dosage (4) 4
placebo (4) 4
randomized controlled trials as topic (4) 4
sglt2 inhibitor (4) 4
sodium (4) 4
thiophenes - administration & dosage (4) 4
thiophenes - adverse effects (4) 4
thiophenes - therapeutic use (4) 4
weight (4) 4
weight loss (4) 4
add-on therapy (3) 3
body mass index (3) 3
canagliflozin - adverse effects (3) 3
clinical outcomes (3) 3
clinical trials (3) 3
diet (3) 3
endocrine system diseases (3) 3
glimepiride (3) 3
glycated hemoglobin (3) 3
hypoglycemia - chemically induced (3) 3
hypoglycemic agents - pharmacology (3) 3
medical research (3) 3
niddm (3) 3
nutritional and metabolic diseases (3) 3
obesity (3) 3
original (3) 3
pooled analysis (3) 3
research (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Journal Article
DIABETES CARE, ISSN 0149-5992, 06/2012, Volume 35, Issue 6, pp. 1232 - 1238
OBJECTIVE-To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus inadequately controlled with... 
TRANSPORT | HYPERGLYCEMIA | INSULIN-SECRETION | ENDOCRINOLOGY & METABOLISM | MELLITUS | PREVALENCE
Journal Article
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 12/2013, Volume 67, Issue 12, pp. 1267 - 1282
AimsCanagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind,... 
BODY-WEIGHT | MEDICINE, GENERAL & INTERNAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | PLACEBO | ADD-ON | DAPAGLIFLOZIN | DOUBLE-BLIND | 2 SGLT2 INHIBITOR | IMPROVES INDEXES | BETA-CELL FUNCTION | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Glucosides - adverse effects | Insulin-Secreting Cells - physiology | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Adolescent | Lipid Metabolism - drug effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Glucose metabolism | Care and treatment | Clinical trials | Hypoglycemic agents | Glucose | Cholesterol | Dextrose | Diabetes therapy | Patient safety | Pharmacology | Diabetes | Drug therapy | Clinical outcomes | Index Medicus | Endocrinology
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 2/2014, Volume 30, Issue 2, pp. 163 - 175
Journal Article
DIABETOLOGIA, ISSN 0012-186X, 06/2015, Volume 58, Issue 6, pp. 1183 - 1187
Aims/hypothesis Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces HbA(1c), body weight and systolic BP (SBP) in patients with type 2... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | BACKGROUND METFORMIN | MONOTHERAPY | Canagliflozin | EFFICACY | SAFETY | Body weight | ENDOCRINOLOGY & METABOLISM | Type 2 diabetes mellitus
Journal Article
DIABETES CARE, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
OBJECTIVE To assess the efficacy/safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, compared with glimepiride over 104 weeks in patients with... 
PLACEBO | ADD-ON | MONOTHERAPY | HYPERGLYCEMIA | SULFONYLUREA | EFFICACY | DAPAGLIFLOZIN | SAFETY | ENDOCRINOLOGY & METABOLISM | NON-INFERIORITY TRIAL | MELLITUS
Journal Article
Journal Article
Journal Article